Repression of T-cell function by thionamides is mediated by inhibition of the activator protein-1/nuclear factor of activated T-cells pathway and is associated with a common structure

Molecular Pharmacology

Volumn 72, Issue 6, 2007, Pages 1647-1656

  Humar, Matjaz ^a,e   Dohrmann, Hannah ^a   Stein, Philipp ^a   Andriopoulos, Nikolaos ^b   Goebel, Ulrich ^a   Heimrich, Bernd ^c   Roesslein, Martin ^a   Schmidt, Rene ^a   Schwer, Christian I ^a   Hoetzel, Alexander ^a   Loop, Torsten ^a   Pahl, Heike L ^a   Geiger, Klaus K ^a   Pannen, Benedikt H J ^d  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^e Center for Clinical Research   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CALMODULIN; CARBIMAZOLE; CD69 ANTIGEN; DIALURIC ACID; DNA; GUANOSINE TRIPHOSPHATASE; INTERLEUKIN 2; MITOGEN ACTIVATED PROTEIN KINASE; PROPYLTHIOURACIL; PROTEIN P21; RAS PROTEIN; THIAMAZOLE; THIOBARBITURIC ACID; THIONAMIDE DERIVATIVE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR NFAT;

ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEPHOSPHORYLATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; HYPERTHYROIDISM; IMMUNE DEFICIENCY; IMMUNOMODULATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN LOCALIZATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

CELL PROLIFERATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JURKAT CELLS; NFATC TRANSCRIPTION FACTORS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES; THIOBARBITURATES; TRANSCRIPTION FACTOR AP-1;

EID: 36348954510     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.038141     Document Type: Article

References (39)

1. Bandyopadhyay U, Biswas K, and Banerjee RK (2002) Extrathyroidal actions of antithyroid thionamides. Toxicol Lett 128:117-127.
2. Cantrell D (1996) T cell antigen receptor signal transduction pathways. Annu Rev Immunol 14:259-274.
3. Castellanos MC, Lopez-Giral S, Lopez-Cabrera M, and de Landazuri MO (2002) Multiple Cis-acting elements regulate the expression of the early T cell activation antigen CD69. Eur J Immunol 32:3108-3117.
4. Castellanos MC, Munoz C, Montoya MC, Lara-Pezzi E, Lopez-Cabrera M, and de Landazuri MO (1997) Expression of the leukocyte early activation antigen CD69 is regulated by the transcription factor AP-1. J Immunol 159:5463-5473.
5. Correa-Sales C, Tosta CE, and Rizzo LV (1997) The effects of anesthesia with thiopental on T lymphocyte responses to antigen and mitogens in vivo and in vitro. Int J Immunopharmacol 19:117-128.
6. Farwell AP and Braverman LE (1996) Thyroid and anti-thyroid drugs, in Goodman and Gilman's the Pharmacological Basis of Therapeutics (Hardman JG and Limbird LE eds), 9th ed, pp 1383-1409, McGraw-Hill, New York.
7. Foletta VC (1996) Transcription factor AP-1, and the role of Fra-2. Immunol Cell Biol 74:121-133.
8. Friday BB and Adjei AA (2005) K-Ras as a target for cancer therapy. Biochim Biophys Acta 1756:127-144.
9. Hardiman O, Molloy F, Brett F, and Farrell M (1997) Inflammatory myopathy in thyrotoxicosis. Neurology 48:339-341.
10. Heo J, Prutzman KC, Mocanu V, and Campbell SL (2005) Mechanism of free radical nitric oxide-mediated ras guanine nucleotide dissociation. J Mol Biol 346:1423-1440.
11. 4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 87:489-499.
12. Hudmon A and Schulman H (2002) Structure-function of the multifunctional Ca2+/calmodulin-dependent protein kinase II. Biochem J 364:593-611.
13. Humar M, Andriopoulos N, Pischke SE, Loop T, Schmidt R, Hoetzel A, Roesslein M, Pahl HL, Geiger KK, and Pannen BH (2004a) Inhibition of activator protein 1 by barbiturates is mediated by differential effects on mitogen-activated protein kinases and the small G proteins Ras and Rac-1. J Pharmacol Exp Ther 311:1232-1240.
14. Humar M, Pischke SE, Loop T, Hoetzel A, Schmidt R, Klaas C, Pahl HL, Geiger KK, and Pannen BH (2004b) Barbiturates directly inhibit the calmodulin/calcineurin complex: a novel mechanism of inhibition of nuclear factor of activated T cells. Mol Pharmacol 65:350-361.
15. Jansson R, Dahlberg PA, Johansson H, and Lindström B (1983) Intrathyroidal concentrations of methimazole in patients with Graves's disease. J Clin Endocrinol Metab 57:129-132.
16. Khandwala HM (2004) A case of congestive heart failure due to reversible dilated cardiomyopathy caused by hyperthyroidism. South Med J 97:1001-1003.
17. King MM (1986) Modification of the calmodulin-stimulated phosphatase, calcineurin, by sulfhydryl reagents. J Biol Chem 261:4081-4084.
18. Loop T, Liu Z, Humar M, Hoetzel A, Benzing A, Pahl HL, Geiger KK, and BH J P (2002) Thiopental inhibits the activation of nuclear factor kappaB. Anesthesiology 96:1202-1213.
19. Macián F, Lopez-Rodriguez C, and Rao A (2001) Partners in transcription: NFAT and AP-1. Oncogene 20:2476-2489.
20. Martí V, Ballester M, Obrador D, Moya C, Carrio I, and Pons-Llado G (1995) Active myocardial damage in hyperthyroidism. A concurrent mechanism of heart failure reversed by treatment. Eur Heart J 16:1014-1016.
21. Molkentin JD (2000) Calcineurin and beyond: cardiac hypertrophic signaling. Circ Res 87:731-738.
22. Nelson BH (2002) Interleukin-2 signaling and the maintenance of self-tolerance. Curr Dir Autoimmun 5:92-112.
23. Nishina K, Akamatsu H, Mikawa K, Shiga M, Maekawa N, Obara H, and Niwa Y (1998) The inhibitory effects of thiopental, midazolam, and ketamine on human neutrophil functions. Anesth Analg 86:159-165.
24. Orgiazzi J and Millot L (1994) Theoretical aspects of the treatment with antithyroid drugs. Ann Endocrinol (Paris) 55:1-5.
25. Passath A, Leb G, and Warnkross H (1987) Pharmacology and dosage of thyrostatic drugs. Acta Med Austriaca 14:72-74.
26. Pastor MI, Woodrow M, and Cantrell D (1995) Regulation and function of P21ras in T lymphocytes. Cancer Surv 22:75-83.
27. Pearce SH (2004) Spontaneous reporting of adverse reactions to carbimazole and propylthiouracil in the UK. Clin Endocrinol (Oxf) 61:589-594.
28. Rao A, Luo C, and Hogan PG (1997) Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 15:707-747.
29. Rincón M, Flavell RA, and Davis RA (2000) The JNK and P38 MAP kinase signaling pathways in T cell-mediated immune responses. Free Radic Biol Med 28:1328-1337.
30. Salman H, Bergman M, Bessler H, Alexandrova S, Beilin B, and Djaldetti M (1998) Effect of sodium thiopentone anesthesia on the phagocytic activity of rat peritoneal macrophages. Life Sci 63:2221-2226.
31. Sebti SM and Hamilton AD (2000) Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-tobedside translational studies. Oncogene 19:6584-6593.
32. 2+-induced conformational transitions in calmodulin with disulfide bonds. J Biol Chem 271:7479-7483.
33. Turcant A, Delhumeau A, Premel-Cabic A, Granry JC, Cotineau C, Six P, and Allain P (1985) Thiopental pharmacokinetics under conditions of long-term infusion. Anesthesiology 63:50-54.
34. Volpé R (2001) The immunomodulatory effects of anti-thyroid drugs are mediated via actions on thyroid cells, affecting thyrocyte-immunocyte signalling: a review. Curr Pharm Des 7:451-460.
35. Wange RL (2000) LAT, the linker for activation of T cells: a bridge between T cell-specific and general signaling pathways. Sci STKE 2000:RE1.
36. Werner MC, Romaldini JH, Bromberg N, Werner RS, and Farah CS (1989) Adverse effects related to thionamide drugs and their dose regimen. Am J Med Sci 297:216-219.
37. Whitmarsh AJ, and Davis RJ (1996) Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med 74:589-607.
38. Wilkins BJ and Molkentin JD (2004) Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem Biophys Res Commun 322:1178-1191.
39. Wittinghofer A, Scheffzek K, and Ahmadian MR (1997) The interaction of Ras with GTPase-activating proteins. FEBS Lett 410:63-67.